Central nervous system (CNS) tumors are a major cause of morbidity and mortality with ~18,000 new cases of primary intracranial tumors diagnosed each year in the United States. This represents ~ 2% of all adult tumors in this country. More than half of these are high-grade gliomas. These lesions are very aggressive and the vast majority of patients invariably have tumor recurrence, with the median survival period ranging from 1 to 3 years after initial diagnosis. Despite facing a better prognosis when compared to higher grade glial tumors, 50–75% of patients harboring low-grade gliomas eventually die of their disease. Median survival durations have been reported to range between 5 and 10 years, and estimates of 10-year survival rates range from 5 to 50%.